Membership Directory
IPSEN
Category: Drug Development
Phone: + (508) 478-0144
Fax: + (508) 473-3531
Website: http://www.ipsen.com
Location: Milford, MA
Ipsen is a global specialty-driven pharmaceutical company with total sales of approximately $1.0 billion in 2010. Ipsen’s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by four franchises: neurology / Dysport®, endocrinology / Somatuline®, uro-oncology / Decapeptyl® and hemophilia. Moreover, the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patient driven platforms, peptides and toxins. In 2010, R&D expenditure was, above 20% of Group sales. The Group has total worldwide staff of close to 4,500 employees.
Ipsen’s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com and www.ipsenus.com.
